This state of hypercoagulability is further increased in the presence of lupus anticoagulant (LA) and anticardiolipin antibodies (aCL), which can be seen in 5–34% and 12–44% of Systemic Lupus Erythematosus (SLE) patients, respectively (37, 38). Here, ACLY is linked to systemic lupus erythematosus.